Literature DB >> 19272368

Ghrelin, paraoxonase and arylesterase levels in depressive patients before and after citalopram treatment.

Abdullah Onder Barim1, Suleyman Aydin, Ramis Colak, Ersel Dag, Omer Deniz, Ibrahim Sahin.   

Abstract

OBJECTIVES: The purpose of this study was to examine alterations in lipid profiles and in the serum concentrations of acylated and desacylated ghrelin, paraoxonase and arylesterase in psychiatric patients before and after treatment with 40 mg citalopram daily for 3 months. DESIGN AND METHODS: Samples were collected from 22 healthy controls and 24 psychiatric patients before and after citalopram treatment. Blood levels of acylated and desacylated ghrelin were measured by radioimmunoassay. Paraoxonase and arylesterase activities were determined spectrophotometrically. Lipid parameters were measured on the OLYMPUS-AU400.
RESULTS: It was found that the levels of acylated, desacylated ghrelin, paraoxonase arylesterase, total cholesterol and triglyceride were lower in depressive patients before citalopram treatment than in the control group. Those parameters were not restored after citalopram treatment except for the arylesterase level.
CONCLUSION: Decreased PON1 and ghrelin levels as well as fluctuations in lipid profiles may be involved in the etiology of depressive disorders.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19272368     DOI: 10.1016/j.clinbiochem.2009.02.020

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  31 in total

Review 1.  Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on.

Authors:  Lucio G Costa; Gennaro Giordano; Clement E Furlong
Journal:  Biochem Pharmacol       Date:  2010-11-18       Impact factor: 5.858

Review 2.  Mood disorders: A potential link between ghrelin and leptin on human body?

Authors:  Stalo Zarouna; Greta Wozniak; Anastasia Ioannis Papachristou
Journal:  World J Exp Med       Date:  2015-05-20

3.  Fasting plasma peptide YY concentrations are increased in patients with major depression who associate weight loss.

Authors:  O Giménez-Palop; R Coronas; J Cobo; L Gallart; J D Barbero; I Parra; G Fusté; J Vendrell; M Bueno; J M González-Clemente; A Caixàs
Journal:  J Endocrinol Invest       Date:  2011-12-15       Impact factor: 4.256

4.  Active ghrelin and the postpartum.

Authors:  Jessica H Baker; Cort Pedersen; Jane Leserman; Kimberly A Brownley
Journal:  Arch Womens Ment Health       Date:  2015-10-01       Impact factor: 3.633

5.  Organophosphate pesticides and PON1 L55M in Parkinson's disease progression.

Authors:  Kimberly C Paul; Janet S Sinsheimer; Myles Cockburn; Jeff M Bronstein; Yvette Bordelon; Beate Ritz
Journal:  Environ Int       Date:  2017-07-06       Impact factor: 9.621

6.  From an Empty Stomach to Anxiolysis: Molecular and Behavioral Assessment of Sex Differences in the Ghrelin Axis of Rats.

Authors:  Stina Börchers; Jean-Philippe Krieger; Ivana Maric; Jil Carl; Maral Abraham; Francesco Longo; Mohammed Asker; Jennifer E Richard; Karolina P Skibicka
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-16       Impact factor: 6.055

7.  Expression of PON1, PON2, PON3 and MPO Genes in Patients with Depressive Disorders.

Authors:  Katarzyna Bliźniewska-Kowalska; Piotr Gałecki; Kuan-Pin Su; Angelos Halaris; Janusz Szemraj; Małgorzata Gałecka
Journal:  J Clin Med       Date:  2022-06-09       Impact factor: 4.964

Review 8.  The Good, the Bad and the Unknown Aspects of Ghrelin in Stress Coping and Stress-Related Psychiatric Disorders.

Authors:  Eva Maria Fritz; Nicolas Singewald; Dimitri De Bundel
Journal:  Front Synaptic Neurosci       Date:  2020-10-27

Review 9.  Ghrelin and Neurodegenerative Disorders-a Review.

Authors:  Limin Shi; Xixun Du; Hong Jiang; Junxia Xie
Journal:  Mol Neurobiol       Date:  2016-01-26       Impact factor: 5.590

Review 10.  Suggested Biomarkers for Major Depressive Disorder.

Authors:  Yunus Hacimusalar; Ertuğrul Eşel
Journal:  Noro Psikiyatr Ars       Date:  2018-05-28       Impact factor: 1.339

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.